Neothetics Incorporated (NASDAQ:NEOT) Short Interest Decreased By 16.87%

July 18, 2017 - By Richard Conner

 Neothetics Incorporated (NASDAQ:NEOT) Short Interest Decreased By 16.87%

The stock of Neothetics Incorporated (NASDAQ:NEOT) registered a decrease of 16.87% in short interest. NEOT’s total short interest was 161,600 shares in July as published by FINRA. Its down 16.87% from 194,400 shares, reported previously. With 97,100 shares average volume, it will take short sellers 2 days to cover their NEOT’s short positions. The short interest to Neothetics Incorporated’s float is 2.54%.

The stock increased 3.89% or $0.018 during the last trading session, reaching $0.478. About shares traded. Neothetics Inc (NASDAQ:NEOT) has risen 106.31% since July 18, 2016 and is uptrending. It has outperformed by 89.61% the S&P500.

Neothetics, Inc. is a clinical-stage specialty pharmaceutical company, which develops therapeutics. The company has market cap of $7.24 million. The Firm focuses on localized fat reduction and body contouring. It currently has negative earnings. It focuses on the development of LIPO-202 for the reduction of central abdominal bulging due to subcutaneous fat in non-obese patients.

Neothetics Inc (NASDAQ:NEOT) Ratings Coverage

Among 2 analysts covering NeoThetics (NASDAQ:NEOT), 0 have Buy rating, 0 Sell and 2 Hold. Therefore 0 are positive. NeoThetics had 2 analyst reports since December 15, 2015 according to SRatingsIntel. The firm earned “Neutral” rating on Tuesday, December 15 by Piper Jaffray. The rating was downgraded by Needham to “Hold” on Tuesday, December 15.

More recent Neothetics Inc (NASDAQ:NEOT) news were published by: Marketwatch.com which released: “Neothetics stock plummets 66% on news of negative results for fat-reduction drug” on June 26, 2017. Also Marketwatch.com published the news titled: “0.4779” on November 20, 2014. Reuters.com‘s news article titled: “BRIEF-Neothetics announces review of strategic alternatives” with publication date: July 10, 2017 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: